CBUS

$3.7

$

Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company is based in San Diego, California.

Next Earnings

2026-02-25

Beta

1.796

Average Volume

Market Cap

Last Dividend

CIK

0001705843

ISIN

US17166A1016

CUSIP

17166A101

CEO

Peter R. Beetham

Sector

Healthcare

Industry

Biotechnology

Full Time Employees

157

IPO Date

2017-07-20

Status

Active

Latest News

Title Headline Publisher Date
Cibus Partnering with The John Innes Centre for UK Government's Farming Innovation Programme Precision Breeding Initiative Cibus to utilize proprietary Rapid Trait Development System™ to enable development of durable resistance to Light Leaf Spot disease, which has caused estimated yield losses of up to £300m in recent years GlobeNewsWire 2026-02-06 07:00:00
Cibus, Inc. Announces Pricing of $20.0 Million Public Offering of Class A Common Stock SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced the pricing of an underwritten public offering of 13,333,333 shares of its Class A Common Stock, par value $0.0001 per share (“Class A Common Stock”), at a public offering price of $1.50 per share (the “Offering”). Members of Cibus' Board of Directors will purchase 1,000,000 shares of Class A Common Stock in the Offering at the public offering price. GlobeNewsWire 2026-01-29 07:00:00
Cibus, Inc. Announces Proposed Public Offering of Class A Common Stock SAN DIEGO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that it intends to offer shares of its Class A common stock, par value $0.0001 per share (“Class A Common Stock”), in an underwritten public offering (the “Offering”). Cibus also expects to grant to the underwriter of the Offering a 30-day option to purchase up to an additional 15% of the shares of Class A Common Stock offered in the Offering on the same terms and conditions. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed or as to the actual size or terms of the Offering. Members of Cibus' Board of Directors (collectively, the “Related Persons”) have indicated an interest in purchasing shares of Class A Common Stock in the Offering. Because these indications of interest are not binding agreements or commitments to purchase, those certain Related Persons may elect not to purchase any shares in the Offering, or the underwriter may elect not to sell any shares in the Offering to those certain Related Persons. GlobeNewsWire 2026-01-28 16:05:00
Cibus and Interoc Advance Rice Commercialization Strategy for Herbicide-Tolerant Traits in Key Markets across Latin America Nonbinding Letter of Intent (LOI) sets framework for potential 2027 market entry in Ecuador and Colombia, followed by expansion into Peru, Central America and the Caribbean Expected to build on success under the existing 2024 material transfer agreement, shifting focus to market execution and revenue generation for co-developed herbicide-tolerant (HT) rice traits SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, and Interoc, a leading provider of agricultural solutions in Latin America, today announced the execution of a non-binding Letter of Intent (LOI). The non-binding LOI establishes a potential framework for the commercialization of co-developed herbicide-tolerant (HT) rice traits in key rice-producing markets across Latin America. GlobeNewsWire 2026-01-05 07:00:00
Cibus Welcomes the Positive Conclusion of Trilogue Negotiations on New Genomic Techniques Legislation Between the European Parliament and Council Political agreement on New Genomic Techniques (NGTs), including gene editing, advances a science-based path for plant breeding innovation and supports Cibus' plans to bring improved traits to European growers GlobeNewsWire 2025-12-11 07:00:00

SEC Filings

Type Filing Date Accepted Date Link
SC 13G/A 2026-02-05 2026-02-05 View Filing
4 2026-02-02 2026-02-02 View Filing
4 2026-02-02 2026-02-02 View Filing
8-K 2026-01-30 2026-01-30 View Filing
424B5 2026-01-30 2026-01-29 View Filing
8-K 2026-01-28 2026-01-28 View Filing
424B5 2026-01-28 2026-01-28 View Filing
8-K 2026-01-06 2026-01-06 View Filing
4 2025-11-25 2025-11-25 View Filing
3 2025-11-25 2025-11-25 View Filing
10-Q 2025-11-13 2025-11-13 View Filing
8-K 2025-11-13 2025-11-13 View Filing
8-K 2025-11-10 2025-11-10 View Filing
4 2025-09-26 2025-09-26 View Filing
3 2025-09-26 2025-09-26 View Filing
8-K 2025-09-23 2025-09-23 View Filing
8-K 2025-09-16 2025-09-16 View Filing
SC 13G/A 2025-08-14 2025-08-14 View Filing
10-Q 2025-08-14 2025-08-14 View Filing
8-K 2025-08-14 2025-08-14 View Filing
8-K 2025-07-23 2025-07-23 View Filing
4 2025-06-11 2025-06-11 View Filing
4 2025-06-10 2025-06-10 View Filing
SC 13D/A 2025-06-10 2025-06-10 View Filing
8-K 2025-06-06 2025-06-06 View Filing
424B5 2025-06-06 2025-06-06 View Filing
8-K 2025-06-04 2025-06-04 View Filing
424B5 2025-06-04 2025-06-04 View Filing
8-K 2025-05-27 2025-05-27 View Filing
4 2025-05-27 2025-05-27 View Filing
4 2025-05-27 2025-05-27 View Filing
4 2025-05-27 2025-05-27 View Filing
4 2025-05-27 2025-05-27 View Filing
4 2025-05-27 2025-05-27 View Filing
4 2025-05-27 2025-05-27 View Filing
8-K 2025-05-23 2025-05-23 View Filing
SC 13G 2025-05-15 2025-05-15 View Filing
10-Q 2025-05-08 2025-05-08 View Filing
8-K 2025-05-08 2025-05-08 View Filing
ARS 2025-04-10 2025-04-10 View Filing
DEFA14A 2025-04-10 2025-04-10 View Filing
DEF 14A 2025-04-10 2025-04-10 View Filing
4 2025-03-28 2025-03-28 View Filing
3 2025-03-28 2025-03-28 View Filing
4 2025-03-28 2025-03-28 View Filing
3 2025-03-28 2025-03-28 View Filing
4 2025-03-27 2025-03-27 View Filing
4 2025-03-27 2025-03-27 View Filing
4 2025-03-27 2025-03-27 View Filing
PRE 14A 2025-03-27 2025-03-27 View Filing
8-K/A 2025-03-27 2025-03-27 View Filing
S-8 2025-03-24 2025-03-24 View Filing
10-K 2025-03-20 2025-03-20 View Filing
8-K 2025-03-20 2025-03-20 View Filing
8-K 2025-02-28 2025-02-28 View Filing
4 2025-02-26 2025-02-26 View Filing
4 2025-02-25 2025-02-25 View Filing
4 2025-02-24 2025-02-24 View Filing
4 2025-02-21 2025-02-21 View Filing
4 2025-02-20 2025-02-20 View Filing
4 2025-02-19 2025-02-19 View Filing
4 2025-02-18 2025-02-18 View Filing
4 2025-02-14 2025-02-14 View Filing
4 2025-02-13 2025-02-13 View Filing
4 2025-02-12 2025-02-12 View Filing
4 2025-02-11 2025-02-11 View Filing
4 2025-02-10 2025-02-10 View Filing
4 2025-02-07 2025-02-07 View Filing
4 2025-02-06 2025-02-06 View Filing
4 2025-02-05 2025-02-05 View Filing
4 2025-02-04 2025-02-04 View Filing
4 2025-02-03 2025-02-03 View Filing
4 2025-01-31 2025-01-31 View Filing
4 2025-01-30 2025-01-30 View Filing
4 2025-01-29 2025-01-29 View Filing
4 2025-01-28 2025-01-28 View Filing
4 2025-01-27 2025-01-27 View Filing
4 2025-01-24 2025-01-24 View Filing
4 2025-01-23 2025-01-23 View Filing
4 2025-01-23 2025-01-23 View Filing
8-K 2025-01-22 2025-01-22 View Filing
4 2025-01-22 2025-01-22 View Filing
4 2025-01-21 2025-01-21 View Filing
424B5 2025-01-21 2025-01-21 View Filing
4 2025-01-17 2025-01-17 View Filing
4 2025-01-15 2025-01-15 View Filing
4 2025-01-14 2025-01-14 View Filing
4 2025-01-13 2025-01-13 View Filing
4 2025-01-10 2025-01-10 View Filing
4 2025-01-10 2025-01-10 View Filing
4 2025-01-10 2025-01-10 View Filing
4 2025-01-08 2025-01-08 View Filing
4 2025-01-07 2025-01-07 View Filing
4 2024-12-20 2024-12-20 View Filing
4 2024-12-19 2024-12-19 View Filing
4 2024-12-18 2024-12-18 View Filing
4 2024-12-16 2024-12-16 View Filing
4 2024-12-13 2024-12-13 View Filing
4 2024-12-12 2024-12-12 View Filing
4 2024-12-11 2024-12-11 View Filing

Algorithm Performance

Upgrade To Premium for Full Access
Algorithm Profit/Loss Profit Factor # Trades Sharpe Sortino Efficiency
Bull Bias 67.98% 1 695 0.04 0.09 64.88
Larry Williams PercentR Strategy 40.37% 0.99 159 0.04 0.09 37.28
Williams PercentR Strategy 40.25% 0.99 298 0.03 0.08 37.15
xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxxx xxx xxxxx
xxxxxxxxxx xxxxx% x xxx xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% x xxx xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% x xxx xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxx xxxxxxx% x xxx xxxx xxxx xxxxx
xxxxxxxxxxxxx xxxxxxx% xxxx x xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xxx xxxx xxxx xxxxx
xxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xxx xxxx xxxx xxxxx
xxx xxxxxxx% x xxx xxxx xxxx xxxx
xxxxxxxxxxxxxxxxxxxxx xxxxxxx% x xx xxxx xxxx xxxx
xxxxxxxxxx xxxxxxx% xxxx xxx x xxxx xxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xxx x xxxx x
xxxxxxxxxxxxxxxxxx xxxxxx% x xx x xxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxx xxxxxx% xxxx xxx x xxxx xxxx
xxxxxxxxxxxxxxxxx xxxxxx% xxxx xx xxxxx x xxxx
xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxx% x xx x xxxx xxxx
xxxxxxxxxxxxx x% x xxx x x xxx
xxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xx x x xxxx
xxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xxx xxxxx x xxx
xxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxx
xxxxxxxxx xxxxxxxx% x xxx xxxxx xxxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xxx xxxxx xxxxx xxxxx
xxxxxxxxxxxx xxxxxxxx% xxxx xxx xxxxx xxxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx x xxxxx xxxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xxx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xxx xxxxx xxxxx xxxx
xxxxxxxxx xxxxxxxx% xxxx xxx xxxxx xxxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xxx xxxxx xxxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xxx xxxxx xxxxx xxxxx
xxxxxxxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxxx
xxxx xxxxxxxx% xxxx xxx xxxxx xxxxx xxxxx
xxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xxx xxxxx xxxxx xxxxx
xxxx xxxxxxxx% xxxx xxx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xxx xxxxx xxxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xxx xxxx xxxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xxx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xxx xxxxx xxxxx xxxxx
xxxxxxxxxxxxxx xxxxxxxx% x xxx xxxxx xxxxx xxxxx